Surrozen (SRZN) Cash from Investing Activities (2020 - 2026)
Surrozen (SRZN) posted quarterly Cash from Investing Activities of -$120000.0 for Q1 2026, down 344.44% year-over-year from $49090.9 in Q1 2025, and down 103.39% quarter-over-quarter from -$59000.0 in Q4 2025.
Surrozen (SRZN) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Surrozen's Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$120000.0 for Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 344.44% year-over-year to -$120000.0; the TTM figure through Mar 2026 stood at -$221000.0 (down 380.43% YoY), while the FY2025 annual figure was -$128000.0, down 392.31% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$120000.0, down from -$59000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was $22.8 million in Q3 2022, with the low at -$412000.0 in Q1 2022.
- The 5-year median for Cash from Investing Activities is -$7000.0 (2024), against an average of $6.0 million.
- The sharpest annual moves came in 2023 and 2026: Cash from Investing Activities jumped 4305.83% in 2023, then sank 344.44% in 2026.
- Surrozen's Cash from Investing Activities stood at $1.9 million in 2022, then surged by 396.6% to $9.5 million in 2023, then slumped by 100.2% to -$19000.0 in 2024, then plunged by 210.53% to -$59000.0 in 2025, then plunged by 103.39% to -$120000.0 in 2026.
- Business Quant data shows SRZN's Cash from Investing Activities at -$120000.0 in Q1 2026, -$59000.0 in Q4 2025, and -$24000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -1.66 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -49.35 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 19.77 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -229.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -363.46 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | -19,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19,000.00 |
| Jun 30, 2026 | -19,000.00 |
| Mar 31, 2026 | -120,000.00 |
| Mar 31, 2026 | -120,000.00 |
| Dec 31, 2025 | -59,000.00 |
| Dec 31, 2025 | -59,000.00 |
| Sep 30, 2025 | -24,000.00 |
| Sep 30, 2025 | -24,000.00 |
| Jun 30, 2025 | -18,000.00 |
| Jun 30, 2025 | -18,000.00 |
| Mar 31, 2025 | -27,000.00 |
| Mar 31, 2025 | -27,000.00 |
| Dec 31, 2024 | -19,000.00 |
| Dec 31, 2024 | -19,000.00 |
| Mar 31, 2024 | -7,000.00 |
| Mar 31, 2024 | -7,000.00 |
| Dec 31, 2023 | 9.50 Mn |
| Dec 31, 2023 | 9.50 Mn |
| Sep 30, 2023 | 7.65 Mn |
| Sep 30, 2023 | 7.65 Mn |